Technology | May 14, 2012

Biosense Webster Launches Thermocool SF Catheter With Curve Visualization


May 14, 2012 — Biosense Webster Inc. launched the new Thermocool SF (surround flow) Nav irrigated ablation catheter with Curve Visualization in the United States during the Heart Rhythm Society (HRS) scientific sessions last week in Boston.

The new irrigated ablation catheter combines Biosense Webster’s latest porous tip technology with the accurate visualization of the Carto3 3-D mapping and ablation system. This enhanced technology is designed to reduce fluoroscopy exposure to physicians, lab staff and patients alike, enhance visualization of the ablation catheters orientation and improve procedural efficiency.
 
The Thermocool SF increased the number of irrigation holes in the tip from six to 56 offers more efficient, uniform cooling than previous catheters.
 
Curve Visualization allows better visualization of the catheter in the Carto3 system. Previously only the tip was shown during procedures. The new system shows 40-90 mm of catheter to better show the orientation of the catheter and how it is supported inside the heart.
 
“The Thermocool SF catheter with Curve Visualization provides substantial advantages over existing technologies,” said Daniel Melby, M.D., cardiac electrophysiologist from the Minneapolis Heart Institute in Minneapolis, Minn., was among the first to use the new technology in the United States.  While using the Curve Visualization feature, the catheter position is more completely represented on the Carto display, thereby allowing less fluoroscopy use and easier catheter positioning on difficult atrial locations. In addition, the Thermocool SF platform provides the ability to consistently ablate at all atrial locations without the limitation of overheating and with 50 less volume delivery to the patient."
 
The catheter is approved in the United States for treatment of drug refractory recurrent symptomatic paroxysmal atrial fibrillation when used with Carto systems and Type 1 atrial flutter for patients 18 years and older.
 
For more information: www.biosensewebster.com
 

Related Content

News

Jan. 20, 2026 — Abbott has received CE Mark in Europe for the TactiFlex Duo Ablation Catheter, Sensor Enabled to treat ...

Home January 22, 2026
Home
News

Jan. 20, 2026 — Kardium Inc. has announced the publication of the PULSAR clinical trial results in the Journal of the ...

Home January 21, 2026
Home
Feature | Kyle Hardner

Robotic Magnetic Navigation (RMN) emerged two decades ago as an alternative approach to performing complex ablation ...

Home January 09, 2026
Home
News

Jan. 6, 2026 — Stereotaxis, a supplier of surgical robotics for minimally invasive endovascular intervention, has ...

Home January 06, 2026
Home
News

Oct. 10, 2025 — Johnson & Johnson MedTech, in collaboration with the Heart Rhythm Clinical and Research Solutions, LLC ...

Home October 13, 2025
Home
News

Sept. 2, 2025 — Johnson & Johnson MedTech has announced acute safety and effectiveness results from the Varipure ...

Home September 05, 2025
Home
News

Sept. 3, 2025 — Kardium Inc. recently announced it has received pre-market approval (PMA) for the Globe Pulsed Field ...

Home September 03, 2025
Home
News

July 14, 2025  –  Johnson & Johnson MedTech has announced U.S. Food and Drug Administration (FDA) approval of an update ...

Home July 14, 2025
Home
News

July 7, 2025 — Catheter ablation is a minimally invasive treatment for abnormal heart rhythms. It is often successful in ...

Home July 09, 2025
Home
News

June 4, 2025 — A new study published in The Annals of Thoracic Surgery, a journal from The Society of Thoracic Surgeons ...

Home June 04, 2025
Home
Subscribe Now